Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

801. Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis

Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis Aleman A, Sommer I E, Kahn R S CRD summary (...) This review compared auditory hallucination rates in schizophrenia after slow repetitive transcranial magnetic stimulation and sham treatment. The authors concluded that the intervention was effective in reducing hallucination rates. These conclusions may not be reliable as the review methodology was poorly reported, the searches were limited, and the included studies had small sample sizes, varying intervention schedules and outcomes and were of uncertain quality. Authors' objectives To evaluate

2007 DARE.

802. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials

Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials Bushe CJ, Leonard BE CRD summary This review assessed the impact of antipsychotic treatment for schizophrenia on glucose parameters. The authors concluded that there was insufficient evidence to reach conclusions (...) is an employee of Eli Lily, the other an occasional speaker for the company. Bibliographic details Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. Journal of Clinical Psychiatry 2007; 68(11): 1682-1690 PubMedID Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Antipsychotic Agents /adverse effects /therapeutic use; Aripiprazole; Benzodiazepines /adverse effects /therapeutic use; Blood Glucose /metabolism; Clozapine

2007 DARE.

803. Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2

Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2 Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

804. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment

Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment Farahati F, Boucher M, Moulton K, Williams R, Herrmann N, Silverman M, Skidmore B Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Farahati F, Boucher M, Moulton K, Williams R, Herrmann N, Silverman M, Skidmore B. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment. Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Report No 91. 2007 Authors' objectives "The aim of this analysis

2007 Health Technology Assessment (HTA) Database.

805. A meta-analysis of cognitive remediation in schizophrenia

A meta-analysis of cognitive remediation in schizophrenia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

806. Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial

Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia (...) for patients with exacerbation of schizophrenia. The study was based on the Ziprasidone Versus Haloperidol in Sequential IM/Oral Treatment (ZIMO) trial. The mean intramuscular doses were 32.1 mg/day for ziprasidone and 14.8 mg/day for haloperidol. Initial and final mean oral doses were, respectively, 113.9 and 137.2 mg/day for ziprasidone and 19 and 17 mg/day for haloperidol. Further details of the intervention strategies were described elsewhere (Perez et al. 2006, see 'Other Publications of Related

2007 NHS Economic Evaluation Database.

807. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia

Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Bounthavong M, Okamoto M P Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three drug treatments for patients with schizophrenia. Specifically, a conventional antipsychotic, haloperidol (HAL), and two newer atypical antipsychotics, risperidone (RIS) and olanzapine (OLA). The dosages assumed were 15 mg/day

2007 NHS Economic Evaluation Database.

808. Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy

Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

809. Review: Adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia: Does adding SSRIs to antipsychotics improve negative symptoms in people with schizophrenia-spectrum disorder?

Review: Adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia: Does adding SSRIs to antipsychotics improve negative symptoms in people with schizophrenia-spectrum disorder? Review: Adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any (...) symptoms in people with schizophrenia Article Text Therapeutics Review: Adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information: 2007

2007 Evidence-Based Mental Health

810. Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia

Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia

2007 Evidence-Based Mental Health

811. Review: Slow repetitive transcranial magnetic stimulation reduces auditory hallucinations in people with schizophrenia

Review: Slow repetitive transcranial magnetic stimulation reduces auditory hallucinations in people with schizophrenia Review: Slow repetitive transcranial magnetic stimulation reduces auditory hallucinations in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Slow repetitive transcranial magnetic stimulation reduces auditory hallucinations in people with schizophrenia Article Text THERAPEUTICS Review

2007 Evidence-Based Mental Health

812. Lifetime risk of suicide in people with schizophrenia lower than commonly reported Full Text available with Trip Pro

Lifetime risk of suicide in people with schizophrenia lower than commonly reported Lifetime risk of suicide in people with schizophrenia lower than commonly reported | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lifetime risk of suicide in people with schizophrenia lower than commonly reported Article Text Prognosis Lifetime risk of suicide in people with schizophrenia lower than commonly reported Free Camilla M Haw , MRCPsych

2006 Evidence-Based Mental Health

813. Review: migrants are at increased risk of developing schizophrenia Full Text available with Trip Pro

Review: migrants are at increased risk of developing schizophrenia Review: migrants are at increased risk of developing schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: migrants are at increased risk of developing schizophrenia Article Text Aetiology Review: migrants are at increased risk of developing schizophrenia Free Michael T Compton , MD, MPH Statistics from Altmetric.com Cantor-Graae E, Selten JP

2006 Evidence-Based Mental Health

814. Glycine and D-serine improve the negative symptoms of schizophrenia Full Text available with Trip Pro

Glycine and D-serine improve the negative symptoms of schizophrenia Glycine and D-serine improve the negative symptoms of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Glycine and D-serine improve the negative symptoms of schizophrenia Article Text Therapeutics Glycine and D-serine improve the negative symptoms of schizophrenia Free Emmanuel Stip , MD, MSc, CSPQ , Louis Eric Trudeau , PhD Statistics from Altmetric.com

2006 Evidence-Based Mental Health

815. People diagnosed with schizophrenia retain the diagnosis long term Full Text available with Trip Pro

People diagnosed with schizophrenia retain the diagnosis long term People diagnosed with schizophrenia retain the diagnosis long term | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here People diagnosed with schizophrenia retain the diagnosis long term Article Text Prognosis People diagnosed with schizophrenia retain the diagnosis long term Free Lars Vedel Kessing , Professor, MD, DMSc Statistics from Altmetric.com Veen ND, Selten JP

2006 Evidence-Based Mental Health

816. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Full Text available with Trip Pro

Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. To study the association between prescribed antipsychotic drugs and outcome in schizophrenia or schizoaffective disorder in the community.Prospective cohort study using national central registers.Community care in Finland.Nationwide cohort of 2230 consecutive adults hospitalised in Finland (...) for the first time because of schizophrenia or schizoaffective disorder, January 1995 to December 2001.Rates of discontinuation of drugs (all causes), rates of rehospitalisation, and mortality associated with monotherapy with the 10 most commonly used antipsychotic drugs. Multivariate models and propensity score methods were used to adjust estimates of effectiveness.Initial use of clozapine (adjusted relative risk 0.17, 95% confidence interval 0.10 to 0.29), perphenazine depot (0.24, 0.13 to 0.47

2006 BMJ

817. Compliance therapy for schizophrenia. (Abstract)

Compliance therapy for schizophrenia. Schizophrenia is a severe mental illness characterised by delusions and hallucinations. Antipsychotic drugs does reduce these symptoms, but at least half of people given these drugs do not comply with the treatment regimen prescribed.To assess the effects of compliance therapy on antipsychotic medication adherence for people with schizophrenia.Cochrane Schizophrenia Group Trials Register (June 2005).We included all randomised controlled trials (...) of 'compliance therapy' for people with schizophrenia or related severe mental disorders.We independently extracted data and, for dichotomous data, calculated the relative risk (RR), its 95% confidence interval (CI) on an intention to treat basis. We present continuous data using the weighted mean difference statistic.We included one trial with relevant and available data (n=56, duration 2 years) comparing compliance therapy with non-specific counseling. The primary outcome 'non-compliance with treatment

2006 Cochrane

818. Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Full Text available with Trip Pro

Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Article Text Prevalence Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Free

2006 Evidence-Based Mental Health

819. Cognitive behavioural therapy reduces short term rehospitalisation compared with psychoeducation in inpatients with schizophrenia Full Text available with Trip Pro

Cognitive behavioural therapy reduces short term rehospitalisation compared with psychoeducation in inpatients with schizophrenia Cognitive behavioural therapy reduces short term rehospitalisation compared with psychoeducation in inpatients with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cognitive behavioural therapy reduces short term rehospitalisation compared with psychoeducation in inpatients with schizophrenia

2006 Evidence-Based Mental Health

820. Stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia Full Text available with Trip Pro

Stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia Stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stable monotherapy with clozapine or olanzapine increases the incidence of diabetes mellitus in people with schizophrenia Article Text Aetiology

2006 Evidence-Based Mental Health